"Prasugrel Hydrochloride" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A piperazine derivative and PLATELET AGGREGATION INHIBITOR that is used to prevent THROMBOSIS in patients with ACUTE CORONARY SYNDROME; UNSTABLE ANGINA and MYOCARDIAL INFARCTION, as well as in those undergoing PERCUTANEOUS CORONARY INTERVENTIONS.
| Descriptor ID |
D000068799
|
| MeSH Number(s) |
D02.886.778.315 D03.383.606.420 D03.383.903.315
|
| Concept/Terms |
LY 640315- LY 640315
- 640315, LY
- LY640315
- LY-640315
|
Below are MeSH descriptors whose meaning is more general than "Prasugrel Hydrochloride".
Below are MeSH descriptors whose meaning is more specific than "Prasugrel Hydrochloride".
This graph shows the total number of publications written about "Prasugrel Hydrochloride" by people in this website by year, and whether "Prasugrel Hydrochloride" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2014 | 0 | 2 | 2 |
| 2016 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
| 2019 | 1 | 1 | 2 |
| 2020 | 0 | 1 | 1 |
| 2021 | 0 | 2 | 2 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Prasugrel Hydrochloride" by people in Profiles.
-
Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Cardiovasc Revasc Med. 2022 08; 41:115-121.
-
Efficacy and safety of prasugrel and clopidogrel in st-segment elevation myocardial infarction in prehospital setting. Am J Emerg Med. 2022 03; 53:254-255.
-
Oral Antiplatelet Therapy After Acute Coronary Syndrome: A Review. JAMA. 2021 Apr 20; 325(15):1545-1555.
-
Oral Antiplatelet Therapy Administered Upstream to Patients With NSTEMI. Crit Pathw Cardiol. 2020 12; 19(4):166-172.
-
Ticagrelor or Prasugrel in Acute Coronary Syndromes - The Winner Takes It All? N Engl J Med. 2019 10 17; 381(16):1582-1585.
-
Prescription Patterns of Clopidogrel, Prasugrel, and Ticagrelor After Percutaneous Coronary Intervention With Stent Implantation (from the NCDR PINNACLE Registry). Am J Cardiol. 2019 12 15; 124(12):1807-1812.
-
Ticagrelor Improves Remodeling, Reduces Apoptosis, Inflammation and Fibrosis and Increases the Number of Progenitor Stem Cells After Myocardial Infarction in a Rat Model of Ischemia Reperfusion. Cell Physiol Biochem. 2019; 53(6):961-981.
-
Multisite Investigation of Outcomes With?Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. JACC Cardiovasc Interv. 2018 01 22; 11(2):181-191.
-
Ticagrelor and Rosuvastatin Have Additive Cardioprotective Effects via Adenosine. Cardiovasc Drugs Ther. 2016 Dec; 30(6):539-550.
-
Are Immature Platelets Growing Up?: Toward a New Marker of Antiplatelet Drug Resistance. J Am Coll Cardiol. 2016 07 19; 68(3):294-296.